Home » Newsletters » BioWorld Science

BioWorld Science

June 30, 2015

View Archived Issues

Volanesorsen named U.S. orphan drug for familial chylomicronemia syndrome

FluBlok Quadrivalent more effective than traditional influenza vaccine

Conatus reports baseline data from first patients in phase IIb trial of emricasan

Immunovaccine and Incyte collaborate to investigate combination of DPX-Survivac and epacadostat

Invenra and Oxford BioTherapeutics collaborate to discover therapeutic antibodies targeting cancer

Phase Ib results for BioChaperone Lispro in type 1 diabetes

SB-204 8% is well-tolerated in subjects with acne vulgaris

Model of cetuximab resistance in CRC allows testing of other treatments

Patrys awards Chinese license for cancer therapy PAT-SC1

Oral suspension formulation of Orfadin receives European approval

Bioiberica to start trials for PRJ-212 for Alzheimer's disease

European orphan drug designation for Cabaletta in spinocerebellar ataxia

Galectin Therapeutics initiates phase II study of GR-MD-02 in NASH

Sarepta Therapeutics completes NDA submission to FDA for eteplirsen

RedHill initiates phase I/II study of ABC-294640 in refractory DLBCL

rF-GM-CSF and rF-TRICOM are safe is patients with bladder carcinoma

Bristol-Myers Squibb develops HCV NS5A inhibitors

Glenmark Pharmaceuticals patents RORgamma-t modulators

Daiichi Sankyo discloses LCAT activators

Merck & Co. reports sGC activators

Shanghai Hansoh Biomedical presents ALK inhibitors

Incyte presents data on INCB-040093

FDA accepts IND for phase I trial of JCAR-017 for relapsed/refractory B-cell NHL

SrtarD6 gene polymorphism in Alzheimer's disease

Intercept files for approval of obeticholic acid for primary biliary cirrhosis in U.S. and E.U.

Bayer files for Japanese approval of BAY-81-8973 for hemophilia A

Novartis to acquire Spinifex Pharmaceuticals

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...